Lead Product(s): Dexamethasone
Therapeutic Area: Ophthalmology Product Name: OXU-001
Highest Development Status: Preclinical Product Type: Small molecule
Deal Size: $37.0 million Upfront Cash: Undisclosed
Deal Type: Financing March 01, 2021
Proceeds will fund planned further clinical development of its lead asset, OXU-001, for the treatment of diabetic macular edema (DME), as well as accelerating development of its early-product pipeline.
Lead Product(s): PAS-nomacopan
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 25, 2021
Recent data from a laser-induced CNV model suggests one dose of long-acting PASylated nomacopan (PAS-nomacopan) reduced neo-vascularisation by the same amount as Eyelea®, a U.S. Food and Drug Administration (FDA)-approved treatment for AMD.